This policy is designed to address medical guidelines that are appropriate for the majority of individuals with a particular disease, illness, or condition. Each person's unique clinical circumstances may warrant individual consideration, based on review of applicable medical records.
Autologous or allogeneic HSCT is considered experimental/investigational, and therefore, non-covered, as a treatment of autoimmune diseases. There is inadequate scientific evidence in peer-reviewed medical literature demonstrating the effectiveness of autologous or allogeneic HSCT for the treatment of autoimmune diseases.
Experimental/Investigational (E/I) services are not covered regardless of place of service.
Services that do not meet the criteria of this policy will be considered experimental/investigational (E/I). A network provider can bill the member for the experimental/investigational service. The provider must give advance written notice informing the member that the service has been deemed E/I. The member must be provided with an estimate of the cost and the member must agree in writing to assume financial responsibility in advance of receiving the service. The signed agreement must be maintained in the provider’s records.